Moderna’s mRNA Covid-19 vaccine shows robust antibody levels at six months, according to a research letter published Tuesday in The New England Journal of Medicine.
Protection from the vaccine is expected to last longer than six months, but we’ll only know how long it works when there is more data from late-stage clinical trials. The company is continuing to study this.
With this research, using three distinct tests that look for antibodies, the scientists found that protective antibody activity remained high in all age groups of the 33 adults involved in this early-stage study.
Younger adults seemed to have higher antibody levels compared to the older groups. Antibody levels are expected to decline over time, but it’s unclear what level of protection this will provide in the real-world. To understand that, there will need to be further studies.
Scientists will continue to monitor these adults to see how long the protection lasts. They will also determine if a booster dose will extend the duration against emerging viral variants.
“Our data show antibody persistence and thus support the use of this vaccine in addressing the Covid-19 pandemic,” the research letter said.
Last week, a separate study showed that the Pfizer/BioNTech Covid-19 vaccine is 91.3% effective six months after the second dose, and 100% effective against severe disease. Moderna’s previous interim results showed it was 94.1% effective, though with less follow-up time.